Medivation (AMEX:MDV)
Historical Stock Chart
From Jul 2019 to Jul 2024
Dutton Associates continues its coverage of Medivation Inc. (AMEX:MDV)
reiterating a Strong Speculative Buy rating and a $22.00 price target.
The 14-page report by Dutton senior analyst Wayne T. Lottinville, CFA is
available at www.jmdutton.com as
well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other
leading financial portals.
Medivation’s recent Phase 2 clinical results
for the treatment of Alzheimer’s disease are
compelling. Not only did Dimebon-treated patients show an improvement
over placebo, but they demonstrated a significant improvement over
baseline for all five endpoints of the study. That is, patients at the
end of the study were actually better off than when they started. An
extension of this trial is currently in progress and could offer
additional clues as to how much Dimebon-treated patients might improve
over a longer treatment period. Based on the dramatic and promising
results from Medivation’s Phase 2 study and on
our perceptions of management’s capabilities,
we believe the Company has a better than average opportunity to clear
regulatory hurdles and ultimately win FDA approval for using Dimebon to
treat Alzheimer’s disease, and perhaps
Huntington’s disease too. Medivation’s
development program using Dimebon to treat Huntington’s
disease is currently is the first part of a two-part Phase 1-2a clinical
study. Medivation expects to file an investigational new drug
application with the FDA in the first quarter of 2007 to begin a
clinical study for treatment of prostate cancer with a group of drug
candidates, its MDV3100 series.
About Dutton Associates
Dutton Associates is one of the largest independent investment research
firms in the U.S. Its 31 senior analysts are primarily CFAs, and have
expertise in many industries. Dutton Associates provides continuing
analyst coverage of over 130 enrolled companies, and its research,
estimates, and ratings are carried in all the major databases serving
institutions and online investors.
The cost of enrollment in our one-year continuing research program is US
$39,500 prepaid for 4 Research Reports, typically published quarterly,
and requisite Research Notes. Dutton Associates received $35,000 from
the Company for 4 Research Reports with coverage commencing on
5/04/2005. We do not accept payment of our fees in company stock. Our
principals and analysts are prohibited from owning or trading in
securities of covered companies. The views expressed in this research
report accurately reflect the analyst's personal views about the subject
securities or issuer. Neither the analyst's compensation nor the
compensation received by us is in any way related to the specific
ratings or views contained in this research report or note. Please read
full disclosures and analyst background at www.jmdutton.com
before investing.